Annual Statements Open main menu

KEWAUNEE SCIENTIFIC CORP /DE/ - Quarter Report: 2004 January (Form 10-Q)

Form 10-Q
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 10-Q

 


 

x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended January 31, 2004

 

¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from              to             

 

Commission file number 0-5286

 


 

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 


 

Delaware   38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

2700 West Front Street

Statesville, North Carolina

  28677
(Address of principal executive offices)   (Zip Code)

 

(704) 873-7202

(Registrant’s telephone number, including area code)

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

As of March 12, 2004, the Registrant had outstanding 2,488,270 shares of Common Stock.

 

Pages: This report, excluding exhibits, contains 18 pages numbered sequentially from this cover page.

 



Table of Contents

KEWAUNEE SCIENTIFIC CORPORATION

 

INDEX TO FORM 10-Q

 

FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2004

 

             Page Number

PART I.      

FINANCIAL INFORMATION

    
Item 1.      

Financial Statements

    
    Condensed Consolidated Statements of Operations – Three months and nine months
ended January 31, 2004 and 2003
   3
    Condensed Consolidated Balance Sheets January 31, 2004 and April 30, 2003    4
    Condensed Consolidated Statements of Cash Flows – Nine months ended January 31,
2004 and 2003
   5
    Notes to Condensed Consolidated Financial Statements    6
Item 2.      

Management’s Discussion and Analysis of Financial Condition and Results of Operations

   10

Review by Independent Auditors

   14

Report by Independent Auditors

   15
Item 3.      

Quantitative and Qualitative Disclosures About Market Risk

   16
Item 4.      

Controls and Procedures

   16
PART II.      

OTHER INFORMATION

    
Item 1.      

Legal Proceedings

   17
Item 6.      

Exhibits and Reports on Form 8-K

   17
SIGNATURE    18

 

2


Table of Contents

Part 1. Financial Information

 

Item 1. Financial Statements

 

Kewaunee Scientific Corporation

Condensed Consolidated Statements of Operations

(Unaudited)

 

    

Three months ended

January 31


   

Nine months ended

January 31


 
     2004

    2003

    2004

    2003

 
     ($ in thousands, except per share data)  

Net sales

   $ 21,454     $ 16,381     $ 70,051     $ 55,691  

Cost of products sold

     17,736       12,919       58,626       45,645  
    


 


 


 


Gross profit

     3,718       3,462       11,425       10,046  

Operating expenses

     3,206       3,361       9,528       9,621  
    


 


 


 


Operating earnings

     512       101       1,897       425  

Interest expense

     (71 )     (35 )     (232 )     (117 )

Other income (expense)

     14       (24 )     163       44  
    


 


 


 


Earnings before income taxes

     455       42       1,828       352  

Income tax expense

     164       —         658       110  
    


 


 


 


Net earnings

   $ 291     $ 42     $ 1,170     $ 242  
    


 


 


 


Net earnings per share-

                                

Basic

   $ 0.12     $ 0.02     $ 0.47     $ 0.10  

Diluted

   $ 0.12     $ 0.02     $ 0.47     $ 0.10  

Weighted average number of common shares outstanding (in thousands)-

                                

Basic

     2,486       2,480       2,485       2,477  

Diluted

     2,499       2,487       2,493       2,486  

 

See accompanying notes to condensed consolidated financial statements.

 

3


Table of Contents

Kewaunee Scientific Corporation

Condensed Consolidated Balance Sheets

(in thousands)

 

    

January 31

2004


   

April 30

2003


 
     (Unaudited)        

Assets

                

Current assets:

                

Cash and cash equivalents

   $ 1,063     $ 520  

Receivables, less allowance

     22,657       16,138  

Inventories

     4,585       5,958  

Deferred income taxes

     103       89  

Prepaid income taxes

     366       1,499  

Prepaid expenses and other current assets

     749       782  
    


 


Total current assets

     29,523       24,986  

Property, plant and equipment, at cost

     33,236       31,926  

Accumulated depreciation

     (21,678 )     (20,135 )
    


 


Net property, plant and equipment

     11,558       11,791  
    


 


Other assets

     6,285       6,877  
    


 


Total Assets

   $ 47,366     $ 43,654  
    


 


Liabilities and Stockholders’ Equity

                

Current liabilities:

                

Short-term borrowings

   $ 6,084     $ 1,416  

Current portion of long-term debt

     1,118       681  

Accounts payable

     5,477       8,338  

Employee compensation and amounts withheld

     1,007       1,203  

Deferred Revenue

     1,738       856  

Other accrued expenses

     741       834  
    


 


Total current liabilities

     16,165       13,328  

Long-term debt

     1,211       1,249  

Deferred income taxes

     1,151       1,150  

Accrued employee benefit plan costs

     1,650       1,634  

Other long-term liabilities

     538       355  
    


 


Total Liabilities

     20,715       17,716  

Stockholders’ equity:

                

Common stock

     6,550       6,550  

Additional paid-in-capital

     134       145  

Retained earnings

     20,758       20,110  

Accumulated other comprehensive income (loss)

     33       (9 )

Common stock in treasury, at cost

     (824 )     (858 )
    


 


Total stockholders’ equity

     26,651       25,938  
    


 


Total Liabilities and Stockholders’ Equity

   $ 47,366     $ 43,654  
    


 


 

See accompanying notes to condensed consolidated financial statements.

 

4


Table of Contents

Kewaunee Scientific Corporation

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands )

 

     Nine months ended
January 31


 
     2004

    2003

 

Cash flows from operating activities:

                

Net earnings

   $ 1,170     $ 242  

Adjustments to reconcile net earnings to net cash used in operating activities:

                

Depreciation

     1,543       1,898  

Provision for bad debts

     62       223  

Decrease in prepaid income taxes

     1,133       180  

Increase in receivables

     (6,581 )     (275 )

Decrease in inventories

     1,373       194  

Decrease in accounts payable and other current liabilities

     (3,150 )     (2,491 )

Increase in deferred revenue

     882       211  

Other, net

     853       234  
    


 


Net cash (used in) provided by operating activities

     (2,715 )     416  
    


 


Cash flows from investing activities:

                

Capital expenditures

     (1,310 )     (3,212 )

Proceeds from sale of fixed assets

     —         366  
    


 


Net cash used in investing activities

     (1,310 )     (2,846 )
    


 


Cash flows from financing activities:

                

Increase in short-term borrowings

     4,668       2,275  

Proceeds from long-term debt

     1,200       —    

Payments on long-term debt

     (801 )     (511 )

Dividends paid

     (522 )     (520 )

Proceeds from exercise of stock options (including tax benefit)

     23       50  

Purchase of treasury stock

     —         —    
    


 


Net cash provided by financing activities

     4,568       1,294  
    


 


Increase (decrease) in cash and cash equivalents

     543       (1,136 )

Cash and cash equivalents, beginning of period

     520       1,747  
    


 


Cash and cash equivalents, end of period

   $ 1,063     $ 611  
    


 


 

See accompanying notes to condensed consolidated financial statements.

 

5


Table of Contents

Kewaunee Scientific Corporation

Notes to Condensed Financial Statements

(unaudited)

 

A. Financial Information

 

The unaudited interim condensed consolidated financial statements of Kewaunee Scientific Corporation (the “Company” or “Kewaunee”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s 2003 Annual Report to Stockholders.

 

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

 

In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the interim periods. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

 

B. Inventories

 

Inventories consisted of the following (in thousands):

 

     Jan. 31, 2004

   April 30, 2003

Finished products

   $ 1,906    $ 2,402

Work in process

     1,178      1,812

Raw materials

     1,501      1,744
    

  

     $ 4,585    $ 5,958
    

  

 

C. Balance Sheet

 

The Company’s April 30, 2003 condensed consolidated balance sheet as presented herein is derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles.

 

6


Table of Contents

D. Segment Information

 

The following table shows net sales and earnings (loss) before income taxes by business segment for three months and nine months ended January 31, 2004 and 2003 (in thousands):

 

    

Laboratory

Products


  

Technical

Products


    Corporate

    Total

Three months ended January 31, 2004

                             

Revenues from external customers

   $ 20,508    $ 946     $ —       $ 21,454

Intersegment revenues

     542      —         (542 )     —  

Segment profit (loss)

     773      (36 )     (282 )     455

Segment Assets

     42,530      —         4,836       47,366

Three months ended January 31, 2003

                             

Revenues from external customers

   $ 15,370    $ 1,011     $ —       $ 16,381

Intersegment revenues

     173      —         (173 )     —  

Segment profit (loss)

     852      (251 )     (559 )     42

Segment Assets

     39,548      —         1,977       41,525

Nine months ended January 31, 2004

                             

Revenues from external customers

   $ 65,850    $ 4,201     $ —       $ 70,051

Intersegment revenues

     1,961      —         (1,961 )     —  

Segment profit (loss)

     2,380      87       (639 )     1,828

Segment Assets

     42,530      —         4,836       47,366

Nine months ended January 31, 2003

                             

Revenues from external customers

   $ 51,649    $ 4,042     $ —       $ 55,691

Intersegment revenues

     518      —         (518 )     —  

Segment profit (loss)

     1,975      (295 )     (1,328 )     352

Segment Assets

     39,548      —         1,977       41,525

 

7


Table of Contents

E. Comprehensive Income

 

A reconciliation of net earnings and total comprehensive income for the three months and nine months ended January 31, 2004 and 2003 is as follows (in thousands):

 

     Three months ended
January 31, 2004


    Three months ended
January 31, 2003


 

Net earnings

   $ 291     $ 42  

Change in fair value of cash flow hedge, net of income tax

     (12 )     2  

Change in cumulative foreign currency translation adjustments

     12       12  
    


 


Total comprehensive income

   $ 291     $ 56  
     Nine months ended
January 31, 2004


    Nine months ended
January 31, 2003


 

Net earnings

   $ 1,170     $ 242  

Change in fair value of cash flow hedge, net of income tax

     (3 )     (35 )

Change in cumulative foreign currency translation adjustments

     45       30  
    


 


Total comprehensive income

   $ 1,212     $ 237  

 

SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities,” requires that the Company record derivatives on the balance sheet at fair value and establishes criteria for designation and effectiveness of hedging relationships. The nature of the Company’s business activities involves the management of various financial and market risks, including those related to changes in interest rates. The Company may from time-to-time employ derivative financial instruments, such as interest rate swap contracts, to mitigate or eliminate certain of those risks. The Company does not enter into derivative instruments for speculative purposes. The Company had one interest rate swap agreement outstanding at January 31, 2004. The Company pays a fixed rate of interest of 6.37% and receives payment based on a variable rate of interest (currently 2.893%) based on a notional amount of $815,000.

 

For the Company’s foreign subsidiaries, assets and liabilities are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in shareholders’ equity.

 

8


Table of Contents

F. Commitments and Contingencies

 

The Company is involved in a legal dispute with Bernards Bros. Inc., a former customer of the Company. The dispute was the subject of lengthy arbitration proceedings completed in December 2000. In June 2003, a judgment was entered in the case against the Company and two other defendants identifying the responsibility for the payment of the Arbitrator’s award. The Company believes that its ultimate liability regarding this matter ranges from $100,000 to $250,000. At January 31, 2004, the Company had an accrual of $134,000 for final settlement of this matter, unchanged from April 30, 2003.

 

G. Stock Options

 

The Company accounts for stock options granted to employees and directors using the intrinsic value method. Under this method no compensation expense is recorded since the exercise price of the stock options is equal to the market price of the underlying stock on the grant date. Had compensation expense for the stock options issued been determined consistent with Financial Accounting Standards Board (“FASB”) Statement No. 123, “Accounting for Stock-Based Compensation,” net earnings and net earnings per share would have been reduced to the following pro forma amounts (in thousands, except per share data):

 

    

Three months ended

January 31, 2004


   

Three months ended

January 31, 2003


 

Net earnings as reported

   $ 291     $ 42  

Pro forma compensation cost

     (20 )     (27 )

Net earnings pro forma

     271       15  

Net earnings per share – Basic

                

As reported

   $ 0.12     $ 0.02  

Pro forma

     0.11       0.01  

Net earnings per share – Diluted

                

As reported

   $ 0.12     $ 0.02  

Pro forma

     0.11       0.01  
    

Nine months ended

January 31, 2004


   

Nine months ended

January 31, 2003


 

Net earnings as reported

   $ 1,170     $ 242  

Pro forma compensation cost

     (60 )     (81 )

Net earnings pro forma

     1,110       161  

Net earnings per share – Basic

                

As reported

   $ 0.47     $ 0.10  

Pro forma

     0.45       0.06  

Net earnings per share – Diluted

                

As reported

   $ 0.47     $ 0.10  

Pro forma

     0.45       0.06  

 

9


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The Company’s 2003 Annual Report to Stockholders contains management’s discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2003. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2003. The analysis of results of operations compares the three months and nine months ended January 31, 2004 with the comparable periods of the prior fiscal year.

 

Results of Operations

 

The Company recorded sales of $21.5 million for the three months ended January 31, 2004, up 31.0% from sales of $16.4 million for the comparable period of the prior year. Sales for the nine months ended January 31, 2004 were $70.1 million, up 25.8% from sales of $55.7 million in the comparable period of the prior year. Sales for the three months and nine months of the current year benefited from a strong order backlog and increased activity in the marketplace for laboratory products. The order backlog was $42.5 million at January 31, 2004, as compared to $46.3 million at October 31, 2003 and $51.5 million at April 30, 2003.

 

Sales of laboratory products increased 33.4% and 27.5% during the three months and nine months ended January 31, 2004, respectively, over the same periods last year. Sales of technical products declined 6.4% and increased 3.9% during the three months and nine months ended January 31, 2004, respectively, as compared to the same periods last year.

 

The gross profit margin for the quarter ended January 31, 2004 was 17.3% of sales, as compared to 21.1% of sales in the same quarter of the prior year. The gross profit margin for the nine months ended January 31, 2004 was 16.3% of sales, as compared to 18.0% of sales in the same period of the prior year. The gross profit margin for the current quarter and nine months of the current year were adversely affected by continued aggressive pricing in the marketplace. The product sales mix for the fourth quarter of the current year is expected to be improved as compared to the third quarter, but remain unfavorable compared to the sales mix in the same period last year. The gross profit margin for the current quarter was also adversely affected by an unfavorable product sales mix. The gross profit margin for the nine months ended January 31, 2003 was adversely affected by $550,000 in charges associated with the relocation of the Company’s technical products business and write-down of related inventories.

 

10


Table of Contents

Operating expenses for the three months ended January 31, 2004 were $3.2 million, or 14.9% of sales, as compared to $3.4 million, or 20.5% of sales, in the same period of the prior year. Operating expenses for the nine months ended January 31, 2004 were $9.5 million, or 13.6% of sales, as compared to $9.6 million, or 17.3% of sales, in the same period of the prior year. Operating expenses for the three and nine month periods ended January 31, 2003 included charges of $262,000 and $441,000, respectively, associated with the relocation of the Company’s technical products business. The improved ratio of expenses to sales in the current year, after excluding the non-recurring charges in the prior year periods, occurred as the dollar levels of operating expenses remained relatively flat, while sales increased.

 

Operating earnings of $512,000 and $1.9 million were recorded for the three months and nine months ended January 31, 2004, respectively. This compares to operating earnings of $101,000 and $425,000 for the comparable periods of the prior year.

 

Interest expense was $71,000 and $232,000 for the three months and nine months ended January 31, 2004, respectively, compared to $35,000 and $117,000 for the same periods of the prior year. The increase in interest expense for the current quarter and year resulted from higher levels of borrowings.

 

Other income was $14,000 and $163,000, in the three months and nine months ended January 31, 2004, respectively, compared to other expense of $24,000 and other income of $44,000 for the comparable periods of the prior year. Other income for the nine months ended January 31, 2004 included $295,000 resulting from the resolution of a disputed claim for laboratory furniture sold by the Company several years ago.

 

Income tax expenses of $164,000 and $658,000 were recorded for the three months and nine months ended January 31, 2004. This compares to income tax expense of $-0- and $110,000 recorded for the three and nine months ended January 31, 2003, respectively. The effective tax rate was approximately 36.0% for quarter and nine months ended January 31, 2004 and was 31.3% for the nine months ended January 31, 2003.

 

Net earnings of $291,000 and $1,170,000, or $.12 per diluted share and $.47 per diluted share, were recorded for the three months and nine months ended January 31, 2004, respectively. This compares to net earnings of $42,000 and $242,000, or $.02 per diluted share and $.10 per diluted share, respectively, for the comparable periods of the prior year.

 

11


Table of Contents

New Accounting Pronouncements

 

In December 2003, the FASB issued a revised SFAS No. 132, “Employers’ Disclosures about Pensions and Other Postretirement Benefits.” The revised SFAS No. 132 revised employers’ disclosures about pension plans and other postretirement benefit plans. It did not change the measurement or recognition of those plans required by SFAS No. 87, “Employers’ Accounting for Pensions,” SFAS No. 88, “Employers’ Accounting for Settlements and Curtailments of Defined Benefit Pension Plans and for Termination on Benefits,” and SFAS No. 106, “Employers’ Accounting for Postretirement Benefits Other than Pensions.” The revised SFAS No. 132 retains the disclosure requirements contained in the original SFAS No. 132. It requires additional disclosures to those in the original SFAS No. 132 about the assets, obligations, cash flows, and net periodic benefit cost of defined benefit pension plans and other defined benefit postretirement plans. The adoption of this new standard did not have an impact on the Company’s financial position, results of operations or cash flows.

 

Liquidity and Capital Resources

 

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings.

 

The Company believes that these sources, will be sufficient to support ongoing business levels, including capital expenditures through the current fiscal year.

 

The Company had working capital of $13.4 million at January 31, 2004, as compared to $11.7 million at April 30, 2003. The ratio of current assets to current liabilities was 1.8–to–1 at January 31, 2004, as compared to 1.9–to–1 at April 30, 2003. At January 31, 2004, advances of $6,084,000 were outstanding under the Company’s revolving credit loan.

 

The Company’s operations used cash of $2,715,000 during the nine months ended January 31, 2004, primarily attributable to an increase in accounts receivable and a decrease in accounts payable, partially offset by the impact of decreases in prepaid income taxes and inventories. The Company’s operations provided cash of $416,000 during nine months ended January 31, 2003, primarily attributable to operating earnings before depreciation, partially offset by decreases in accounts payable and other current liabilities.

 

12


Table of Contents

During the nine months ended January 31, 2004, the Company used cash of $1,310,000 in investing activities, primarily for purchases of production equipment. This compares to the use of $2,846,000 for similar investing activities in the same period of the prior year.

 

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

 

Certain statements in this report constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, products, services, and prices. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by the Company prior to the effective date of the Reform Act. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms “believes”, “belief”, “expects”, “plans”, “objectives”, “anticipates”, “intends” or the like to be uncertain and forward-looking.

 

13


Table of Contents

REVIEW BY INDEPENDENT AUDITORS

 

A review of the interim financial information included in this Quarterly Report on Form 10-Q for the three months and nine months ended January 31, 2004 has been performed by PricewaterhouseCoopers LLP, the Company’s independent auditors. Their report on the interim financial information follows.

 

14


Table of Contents

REPORT OF INDEPENDENT AUDITORS

 

To the Board of Directors and Stockholders of

Kewaunee Scientific Corporation

Statesville, North Carolina

 

We have reviewed the accompanying condensed consolidated balance sheet of Kewaunee Scientific Corporation as of January 31, 2004 and April 30, 2003, and the related condensed consolidated statements of operations for each of the three and nine-month periods ended January 31, 2004 and January 31, 2003 and the condensed consolidated statement of cash flows for the nine-month periods ended January 31, 2004 and January 31, 2003. These financial statements are the responsibility of the Company’s management.

 

We conducted our review in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

 

Based on our review, we are not aware of any material modifications that should be made to the accompanying condensed consolidated interim financial information for them to be in conformity with accounting principles generally accepted in the United States of America.

 

We previously audited in accordance with auditing standards generally accepted in the United States of America, the consolidated balance sheet as of April 30, 2003, and the related consolidated statements of operations, of stockholder’s equity, and of cash flows for the year then ended (not presented herein), and in our report dated June 4, 2003 we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of April 30, 2003 is fairly stated in all material respects in relation to the consolidated balance sheet from which it has been derived.

 

PricewaterhouseCoopers LLP

Charlotte, North Carolina

February 23, 2004

 

15


Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2003.

 

Item 4. Controls and Procedures

 

(a) Evaluation of disclosure controls and procedures

 

An evaluation was performed under the supervision and the participation of the company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of January 31, 2004. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of January 31, 2004, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

 

(b) Changes in internal controls

 

There were no significant changes in the Company’s internal controls or in other factors that could significantly affect these controls subsequent to January 31, 2004. As no significant deficiencies or material weaknesses were found, no corrective actions were taken.

 

16


Table of Contents

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

The Company is involved in a legal dispute with Bernards Bros. Inc., a former customer of the Company. The dispute was the subject of lengthy arbitration proceedings completed in December 2000. In June 2003, a judgment was entered in the case against the Company and two other defendants identifying the responsibility for the payment of the Arbitrator’s award. The Company believes that its ultimate liability regarding this matter ranges from $100,000 to $250,000. At January 31, 2004, the Company had an accrual of $134,000 for final settlement of this matter, unchanged from April 30, 2003.

 

Item 6. Exhibits and Reports on Form 8-K

 

(a) Exhibits

 

  31.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  31.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

(b) Reports on Form 8-K

 

A Form 8-K was filed on November 21, 2003, with the Commission which included as an exhibit the Company’s Press Release announcing the financial results for the three months and six months ended October 31, 2003.

 

17


Table of Contents

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

KEWAUNEE SCIENTIFIC CORPORATION

(Registrant)

 

Date: March 16, 2004

   By   

/s/ D. Michael Parker


          D. Michael Parker
          Senior Vice President, Finance and
          Chief Financial Officer

 

18